$5995 | Single User
$8995 | Global License

Medical Affairs Reputations: Renal Cell Carcinoma (US)

Published by FirstWord Pharma: 01 Apr 2016 | 329 | In Stock

Introduction

Introduction


Opdivo’s medical affairs team working overtime to engage oncologists. Is it paying off?


Opdivo’s medical affairs team has been busy. Since late 2015, when the Anti-PD-1 monoclonal antibody got FDA approval for renal cell carcinoma (RCC) treatment, they’ve been one of the most active teams in the US market.


Is it paying off?


Find out how oncologists rate Opdivo’s team, and how the teams for 7 other major RCC treatments measure up, in Medical Affairs Reputations: RCC.


You’ll learn whether your team is giving oncologists the services they want, whether they’re satisfied with your performance, and where you need the most improvement.


Puchase Reasons


Answering Key Questions about Medical Affairs Teams for 8 Major RCC Brands


  • Afinitor (everolimus; Novartis): Are oncologists more satisfied with Afinitor’s team or Votrient’s?

  • Avastin (bevacizumab; Genentech): Which brand’s team is tied with Avastin’s for overall quality of interactions?

  • Inlyta (axitinib; Pfizer): Does Inlyta’s team outperform Votrient’s?

  • Opdivo (nivolumab; BMS): Performance scores for Opdivo’s team are mostly middle of the pack, but it excels in two areas. Which two?

  • Proleukin (aldesleukin; Prometheus): Proleukin’s team gets high performance and satisfaction scores in most areas. How does it rank for overall quality of interactions?

  • Sutent (sunitinib; Pfizer): Sutent’s team is one of the leading teams in Europe. How is it doing in the US?

  • Torisel (temsirolimus; Pfizer): Is Torisel’s team better at responding promptly to inquiries or providing scientific and product information?

  • Votrient (pazopanib; Novartis): Has Votrient’s team interacted with more oncologists than Afinitor’s, Avastin’s, or Inlyta’s in the last 6 months?

  • Top Takeaways


  • Huge lead for #1 team: Despite average performance and satisfaction scores in several areas, its overall quality rating is more than double that of its closest competitor.

  • Stiff competition downmarket: Rated for overall quality of interactions, a mere 2 points separate the 2nd place team from the 5th place team.

  • Unmet need in the market: The way oncologists use medical affairs teams right now suggests high levels of unmet need in the market.

  • Oncologists hungry for information: They say the most important medical affairs services involve providing information and clinical support.

  • Solid performance: Scores are moderately high to high—especially in important areas. Some of the highest go to the team with the lowest overall quality rating.

  • Several areas need improvement: Most teams need to improve satisfaction in 3 to 4 of the 6 services most important to oncologists.

  • Satisfaction is high, but not across the board: Several teams earn high scores in most areas, but others lag.

  • Oncologists prefer meeting face-to-face: In-person interaction types rank higher than electronic interactions and phone calls, although email is fairly well tolerated.

  • An Expert-designed Competitive View of Your Medical Affairs Team


    Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams—answering important questions like:


    What do oncologists need?


  • How, and how often are they using your medical affairs team?

  • What services do they consider most important?

  • How often should you contact them? What channels are best?

  • Does your medical affairs team deliver?


  • How memorable are your team’s interactions with oncologists?

  • How do oncologists rank your team for performance and satisfaction in 12 key areas?

  • How does your team compare to the competition—in each area, and overall?

  • What needs improvement?


  • Are you delivering the services that are most important to oncologists?

  • Where do you need to improve?

  • How can your team enhance its services?

  • Based on Interviews with Practicing Oncologists


    We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.


    All respondents:


  • Have been practicing for between 3 and 35 years

  • See at least 5 patients with NSCLC in a typical month

  • Devote at least 50% of their time to direct patient care

  • Have interacted with at least one listed product’s medical affairs team in the last 6 months.

  • We conducted the survey between March 2nd and March 17th, 2016.


    MONEY BACK GUARANTEE!


    At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll

    refund your money. Guaranteed.


    About FirstWord


    FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and

    MedTech professionals worldwide. FirstWord offers a range of products and services designed to help

    your company gain a competitive edge by making key business decisions with speed and

    confidence.


    FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering

    up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s

    success.


    FirstWord Reports deliver timely, need-to-know intelligence about your products, your

    competitors and your markets. Covering biosimilars, market access, medical affairs, sales &

    marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on

    the challenges facing pharma today.

    Table of Contents
    for Medical Affairs Reputations: Renal Cell Carcinoma (US)

    • 1 Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary

      2 Current Status of Interactions with Different Medical Affairs Teams

      2.1 Interactions in the past 6 months with Medical Affairs teams for each product

      2.2 Current frequency of interactions with medical affair teams for each product

      3 Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes

      3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product

      3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice

      3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes

      3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams

      3.5 Need-Gap analysis by product

      4 Preferred Interaction Media, Frequency, and Suggestions for Improvement

      4.1 Preferred interaction media and frequency, and suggestions for improvement

      5 Appendix

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    329 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Building Strong Cross-Functional Medical Affairs Teams
    IntroductionCould your Medical Affairs team be better integrated for more effective cross-functional...
    01 May 2015 by FirstWord Pharma USD $695 More Info
    Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders
    IntroductionBased on survey results from 150 rheumatologists, dermatologists, and gastroenterologist...
    01 Feb 2015 by FirstWord Pharma USD $5,995 More Info
    Physician Views: How do endocrinologists value diabetes-focused medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    08 Dec 2014 by FirstWord Pharma USD $695 More Info
    Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies
    IntroductionAs the cancer drug market continues to face significant challenges in an environment of ...
    02 Dec 2014 by FirstWord Pharma USD $3,900 More Info
    Reshaping Medical Affairs: delivering value to KOLs and payers
    IntroductionHistorically, the key role of Medical Affairs was supporting the initial regulatory appr...
    21 Aug 2014 by FirstWord Pharma USD $695 More Info
    Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies
    IntroductionAs the oncology drug market continues to face significant road bumps in terms of develop...
    14 Aug 2014 by FirstWord Pharma USD $3,900 More Info
    Physician Views: How do pulmonologists value medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    09 Jul 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    18 Jun 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: How do oncologists value medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    22 May 2014 by FirstWord Pharma USD $695 More Info
    Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value
    IntroductionIn this era of transparency, Medical Affairs is rapidly becoming the new voice of Pharma...
    01 May 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Medical Affairs Reputations: Renal Cell Carcinoma (US) | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • Allied Market Research
    • CBR Pharma
    • Current Partnering
    • Firstword
    • Global Data
    • Global Markets Direct
    • ICD Research
    • Infinti Research Technavio
    • Marketline
    • Markets and Markets
    • Micro Markets Monitor
    • MP Advisors
    • Venture Planning Group
    • GMR Data